All the benefits of molecular testing
in an affordable and easy-to-use system.
Using next-generation technology, and a customer-centric business model, Great Basin is making fast and accurate molecular diagnostics possible for every hospital and lab.
Company receives CE marking; customer evaluations have begun for first multiplex panel, delivering healthcare providers in U.S. and Europe a new resource for antimicrobial stewardship Salt Lake City, September 20, 2016 – Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, announced today the U.S. and European commercial launch of its Staph ID/R Blood Culture […]View Post View/Download PDF
Here are 137 entrepreneurs in the healthcare space who are innovating in the medical, IT, consumer and medical professional fields. Ryan Ashton is president and CEO of Great Basin Scientific, a publicly held molecular diagnostics company that commercializes technologies to improve ease-of-use and deliver better cost per result for sample-to-result molecular diagnostic testing.
Laura Dyrda, Becker’s Hospital ReviewView Link
View All Posts